Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cell Transplantation for ACLF
NCT03863002Phase 2Unknown
- Sponsor
- Tianjin Weikai Bioeng
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of mesenchymal stem cells in acute-on-chronic liver failure (ACLF), sponsored by Tianjin Weikai Bioeng. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT03863002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03863002.